1 week Ago By Defense World Staff
American Century Companies Inc. boosted its position in Inogen, Inc. ( NASDAQ:INGN – Free Report ) by 10.
2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 54,856 shares of the medical technology company’s stock after acquiring an additional 5,089 shares during the period. American Century Companies Inc.
owned 0.23% of Inogen worth $503,000 as of its most recent SEC filing. A number of other hedge funds have also recently added to or reduced their stakes in INGN.
BNP Paribas Financial Markets lifted its holdings in shares of Inogen by 13.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 42,137 shares of the medical technology company’s stock worth $409,000 after purchasing an additional 5,131 shares in the last quarter.
Verition Fund Management LLC bought a new position in shares of Inogen in the third quarter valued at $106,000. Centiva Capital LP acquired a new position in shares of Inogen during the third quarter valued at about $138,000. State Street Corp increased its position in shares of Inogen by 2.
8% during the third quarter. State Street Corp now owns 511,018 shares of the medical technology company’s stock worth $4,957,000 after acquiring an additional 14,054 shares in the last quarter. Finally, Barclays PLC raised its holdings in shares of Inogen by 72.
9% in the 3rd quarter. Barclays PLC now owns 55,508 shares of the medical technology company’s stock worth $539,000 after acquiring an additional 23,398 shares during the last quarter. Institutional investors and hedge funds own 89.
94% of the company’s stock. Analysts Set New Price Targets A number of brokerages have commented on INGN. StockNews.
com lowered Inogen from a “buy” rating to a “hold” rating in a report on Wednesday, February 26th. Needham & Company LLC reiterated a “hold” rating on shares of Inogen in a report on Wednesday. Inogen Price Performance INGN opened at $7.
31 on Friday. Inogen, Inc. has a fifty-two week low of $6.
40 and a fifty-two week high of $13.33. The firm has a market capitalization of $196.
54 million, a P/E ratio of -3.25 and a beta of 1.48.
The company’s 50-day moving average is $8.33 and its 200 day moving average is $9.23.
About Inogen ( Free Report ) Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Featured Stories Five stocks we like better than Inogen How to Invest in Insurance Companies: A Guide Robinhood Strategies Could Be a Game-Changer for Young Investors Business Services Stocks Investing Are These 3 Retail Stocks Oversold or Really in Trouble? What Investors Must Know About Over-the-Counter (OTC) Stocks IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.
com's FREE daily email newsletter ..
